Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of subcutaneous LEO 138559 in adults with moderate-to-severe atopic dermatitis
2022-500777-14-00Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of temtokibart in atopic dermatitis (AD) (3 arms), sponsored by LEO Pharma. Primary endpoint: Percent change in EASI score from baseline to Week 16. Started Oct 2023; status: completed.
02
Drugs
temtokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-500777-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500777-14-00.